Despite this success, the response rate of ICB was generally less than 30%, and single‐agent PD‐1 inhibitors reported response rates of only 10%–17% for unselected patients with metastatic gastroesophageal cancer,6, 7 indicating additional non‐redundant immunomodulation pathways might attenuate antitumour immunity in gastric cancer. Here, PDCD1 is linked to gastric cancer.